Kristen N. Balogh

BioNTech (United States) — United States

Medicine · Health Sciences

7h-index1.1kcitations22works8.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Immunotherapy and Biomarkers(11), Immunotherapy and Immune Responses(11), CAR-T cell therapy research(5), Macrophage Migration Inhibitory Factor(5), vaccines and immunoinformatics approaches(4)

Publications22 total

NEO-STIM advances personalized neoantigen-specific adoptive T cell therapy
Nature Communications·2026Open Access
Publisher Correction: Personalized, autologous neoantigen-specific T cell therapy in metastatic melanoma: a phase 1 trial
Nature Medicine·2025Open Access
Personalized, autologous neoantigen-specific T cell therapy in metastatic melanoma: a phase 1 trial
Nature Medicine·2025· 32 citedOpen Access
BNT321, a novel monoclonal antibody targeting sialyl Lewis A: Phase 1 monotherapy and combination with mFOLFIRINOX in patients with advanced CA19-9 expressing cancers.
Journal of Clinical Oncology·2024· 1 cited
769 Interim clinical and translational data from NTC-001, a phase I study to evaluate the non-engineered neoantigen-specific T cell product BNT221 in patients with advanced or metastatic melanoma
Regular and Young Investigator Award Abstracts·2023Open Access
Personalized neoantigen vaccine NEO-PV-01 with chemotherapy and anti-PD-1 as first-line treatment for non-squamous non-small cell lung cancer
Cancer Cell·2022· 202 cited
Myeloid Derived Suppressor Cells Migrate in Response to Flow and Lymphatic Endothelial Cell Interaction in the Breast Tumor Microenvironment
Cancers·2022· 16 citedOpen Access
Abstract 73: A personal neoantigen vaccine NEO-PV-01 in combination with chemotherapy and pembrolizumab induces broad de novo immune responses in first-line non-squamous NSCLC: Associations with clinical outcomes
Cancer Research·2021· 4 cited
364 A personal neoantigen vaccine NEO-PV-01 in combination with chemotherapy and pembrolizumab induces broad de novo immune responses in first line, non-squamous NSCLC
Regular and Young Investigator Award Abstracts·2020Open Access
Combined TCR Repertoire Profiles and Blood Cell Phenotypes Predict Melanoma Patient Response to Personalized Neoantigen Therapy plus Anti-PD-1
Cell Reports Medicine·2020· 45 citedOpen Access
A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer
Cell·2020· 701 citedOpen Access
Abstract 5006: Comprehensive gene expression analysis of the tumor microenvironment in patients with advanced cancer treated with a personalized neoantigen vaccine, NEO-PV-01, in combination with anti-PD1
Cancer Research·2019· 1 cited
Abstract 942: The personalized vaccine, NEO-PV-01 with anti-PD1, induces neoantigen-specific de novo immune responses in patients with advanced metastatic melanoma: Association with clinical outcomes
Clinical Research (Excluding Clinical Trials)·2019
Abstract 942: The personalized vaccine, NEO-PV-01 with anti-PD1, induces neoantigen-specific de novo immune responses in patients with advanced metastatic melanoma: Association with clinical outcomes
Cancer Research·2019· 8 cited
Abstract 5006: Comprehensive gene expression analysis of the tumor microenvironment in patients with advanced cancer treated with a personalized neoantigen vaccine, NEO-PV-01, in combination with anti-PD1
Clinical Research (Excluding Clinical Trials)·2019· 1 cited
The role of Macrophage Migration Inhibitory Factor (MIF) in anti-tumor immune responses and metastatic niche formation in breast cancer
Libra·2018Open Access
Macrophage Migration Inhibitory Factor protects cancer cells from immunogenic cell death and impairs anti-tumor immune responses
PLoS ONE·2018· 104 citedOpen Access
Balogh et al. PLOS One Underlying Data Files
Arabixiv (OSF Preprints)·2018
Abstract A03: A role for Macrophage Migration Inhibitory Factor (MIF) in breast cancer growth and metastasis
Cancer Immunology Research·2017
Abstract A152: The macrophage migration inhibitory factor promotes breast cancer metastasis through interaction with the host immune response
Cancer Immunology Research·2016· 1 cited
page 1 of 2Next →

Frequent Co-authors

Richard B. Gaynor(13), Meghan E. Bushway(9), Tracey Sciuto(9), Mark DeMario(9), Lakshmi Srinivasan(9), Victoria Kohler(8), Melissa A. Moles(8), Michael S. Rooney(8), Jesse Z. Dong(7), Rana H. Besada(6), Julian Scherer(6), Asaf Poran(6), John Srouji(6), Janet V. Cross(6), Ying S. Ting(5), Yvonne Ware(5), Lisa D. Cleary(5), Kelledy Manson(5), Joel Greshock(5), April Lamb(5)